All In Biotech

Drug Trial Radar · NCT02363998

Open-Label, Safety Study of Lofexidine

A Phase 3, Open-Label, Safety Study of Lofexidine

Last checked: Nov 20, 2026Latest source record: Mar 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

286

Actual

Start

Feb 2015

Primary completion

Sep 2015

Study completion Oct 2015

Sponsor

Lead sponsor
USWM, LLC (dba US WorldMeds)Industry
Sponsor type
Industry
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Feb 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and buprenorphine. This study will take place in a variety of clinical scenarios, both in-clinic and outpatient settings.

Conditions

  • Opioid Withdrawal

Interventions

  • LofexidineDrug

    All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Days 1-14
  2. Overall Occurrence of Serious Treatment Emergent Adverse Events (Serious TEAEs)Time frame: Days 1-14
  3. Overall Treatment Emergent Adverse Events (TEAEs) by SeverityTime frame: Days 1-14
  4. Occurrence of Per Protocol Adverse Events of Special Interest (AESI)Time frame: Day 1 to Day 14
  5. Occurrence of Adverse Events (AEs) Not Related to Opioid WithdrawalTime frame: Day 1 to Day 14
  6. Mean Observed and Change From Screening in Seated Systolic Blood Pressure (mmHg): Vital SignTime frame: Day 1 to Day 14
  7. Mean Observed and Change From Screening in Standing Systolic Blood Pressure (mmHg): Vital SignTime frame: Day 1 to Day 14
  8. Mean Observed and Change From Screening in Seated Diastolic Blood Pressure (mmHg): Vital SignTime frame: Day 1 to Day 14
  9. Mean Observed and Change From Screening in Standing Diastolic Blood Pressure (mmHg): Vital SignTime frame: Day 1 to Day 14
  10. Mean Observed and Change From Screening in Seated Pulse (Bpm): Vital SignsTime frame: Day 1 to Day 14
  11. Mean Observed and Change From Screening in Standing Pulse (Bpm): Vital SignsTime frame: Day 1 to Day 14
  12. Columbia Suicide Severity Rating Scale Questionnaire (C-SSRS): Suicidal Ideation and Behavior NumbersTime frame: Day 1 to Day 14
  13. Clinical Laboratory Test Change From Baseline: HematologyTime frame: Day 1 to Day 14
  14. Clinical Laboratory Test Change From Baseline: ChemistryTime frame: Day 1 to Day 14
  15. Clinical Laboratory Test Change From Baseline: UrinalysisTime frame: Day 1 to Day 7
  16. Safety Electrocardiograms (ECG) Evaluation Shift From Baseline to Post Dose and End of StudyTime frame: Day 1 and Day 14

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Springdale, Arkansas

  • Site not named

    San Diego, California

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Winfield, Illinois

  • Site not named

    Lake Charles, Louisiana

  • Site not named

    Rockville, Maryland

  • Site not named

    Flowood, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    New York, New York

  • Site not named

    Dayton, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    North Charleston, South Carolina

  • Site not named

    Orem, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.